We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pharma Stock Roundup: Pfizer, Allergan Q3 Results Fall Short, Insulin Drugmakers under Pricing Pressure
Read MoreHide Full Article
This week, key earnings updates came from companies like Pfizer (PFE - Free Report) and Allergan while pharma stocks remained under drug pricing pressure with lawmakers questioning the prices of insulin drugs.
Recap of the Week’s Most Important Stories
Pfizer, Allergan Disappoint in Q3: Pfizer’s third quarter results were disappointing with the company missing on both earnings and revenues. The company also announced that it will be dropping the development of its late-stage PCSK9 inhibitor, bococizumab -- this decision was based on the emerging clinical profile as well as the market landscape (Read more: Pfizer Q3 Earnings Lag; Cuts View, Sheds Bococizumab).
Meanwhile, Allergan’s third quarter results were also disappointing -- the company, which had surpassed expectations in each of the first two quarters of 2016, missed earnings as well as revenue expectations in the third quarter (Read more: Allergan Lags Q3 Earnings, Cuts View, Ups Buyback).
Generic Stocks in Trouble?: Last week, several companies with a presence in the generic segment saw their share prices slide following a Bloomberg article that the Department of Justice (DoJ) could file price collusion charges against these companies by year end. According to the article, the DoJ investigation started a couple of years back and covers more than 12 companies and about 24 drugs. A grand jury is examining whether some of the executives colluded with each other to raise prices. Companies like Lannett, Impax and Endo were among stocks that were hit hard by the news. Other companies with a presence in the generics market also saw their shares slide.
Insulin Drugmakers Feel the Pricing Pressure: Insulin drugmakers like Lilly (LLY - Free Report) and Novo Nordisk are also under attack with Senator Bernie Sanders posting a series of tweets questioning the prices of their insulin drugs. Moreover, Sen. Sanders and Rep. Cummings have asked the Justice Department and the Federal Trade Commission (FTC) to investigate potential collusion among pharmaceutical companies that manufacture diabetes products.
According to the lawmakers, insulin medication prices have tripled between 2002 and 2013, from $231 to $736 per year per patient. As per information provided in the letter to the DoJ and the FTC, the price of Sanofi’s Lantus shot up 168% from 2010 to 2014 while that of Lilly’s Humalog shot up 103% and that of Merck’s (MRK - Free Report) Januvia and Janumet by 75% each. Merck is a Zacks Rank #2 (Buy) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Novartis Breast Cancer Treatment Gets Priority Review: Novartis’ (NVS - Free Report) experimental breast cancer treatment, LEE011 (ribociclib) was granted Priority Review by the FDA for the first-line treatment of postmenopausal women with HR+/HER2- advanced or metastatic breast cancer in combination with Femara (letrozole). LEE011 plus Femara was shown to reduce the risk of progression or death by 44% compared to Femara alone. The candidate is also being reviewed by the European Medicines Agency (EMA).
Astellas to Acquire Ganymed, Strengthen Cancer Pipeline: Astellas Pharma announced that it will be acquiring Germany based Ganymed Pharmaceuticals AG, a biopharmaceutical company focused on the development of a new class of immunotherapeutic cancer drugs called ideal monoclonal antibodies (IMABs).
The acquisition could see Astellas shelling out up to €1.282 billion including €422 million for 100% of the equity in Ganymed. The balance would be payable on the achievement of milestones related to the development of IMAB362, which is being evaluated for cancer, a key focus areas as well as growth driver for Astellas. IMAB362 has orphan drug status in the U.S. and Europe for gastric and pancreatic cancer.
Pfizer’s shares declined 6.0% reflecting the disappointing earnings report. The NYSE ARCA Pharmaceutical Index declined 2.3% over the last five trading days. Over the last six months, Bristol-Myers (BMY - Free Report) declined 27.9% while Merck was up 7.3% (See the last pharma stock roundup here: Bristol-Myers, Merck Top Estimates, Merck Wins Key FDA Nod).
What's Next in the Pharma World?
Companies like Mylan, Endo and AstraZeneca (AZN - Free Report) will be reporting earnings results in the coming days. Moreover, a decision from the FDA regarding Bristol-Myers’ Opdivo for head and neck cancer should be out by Nov 11.
Now See Our Private Investment Ideas
While the above ideas are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pharma Stock Roundup: Pfizer, Allergan Q3 Results Fall Short, Insulin Drugmakers under Pricing Pressure
This week, key earnings updates came from companies like Pfizer (PFE - Free Report) and Allergan while pharma stocks remained under drug pricing pressure with lawmakers questioning the prices of insulin drugs.
Recap of the Week’s Most Important Stories
Pfizer, Allergan Disappoint in Q3: Pfizer’s third quarter results were disappointing with the company missing on both earnings and revenues. The company also announced that it will be dropping the development of its late-stage PCSK9 inhibitor, bococizumab -- this decision was based on the emerging clinical profile as well as the market landscape (Read more: Pfizer Q3 Earnings Lag; Cuts View, Sheds Bococizumab).
Meanwhile, Allergan’s third quarter results were also disappointing -- the company, which had surpassed expectations in each of the first two quarters of 2016, missed earnings as well as revenue expectations in the third quarter (Read more: Allergan Lags Q3 Earnings, Cuts View, Ups Buyback).
Generic Stocks in Trouble?: Last week, several companies with a presence in the generic segment saw their share prices slide following a Bloomberg article that the Department of Justice (DoJ) could file price collusion charges against these companies by year end. According to the article, the DoJ investigation started a couple of years back and covers more than 12 companies and about 24 drugs. A grand jury is examining whether some of the executives colluded with each other to raise prices. Companies like Lannett, Impax and Endo were among stocks that were hit hard by the news. Other companies with a presence in the generics market also saw their shares slide.
Insulin Drugmakers Feel the Pricing Pressure: Insulin drugmakers like Lilly (LLY - Free Report) and Novo Nordisk are also under attack with Senator Bernie Sanders posting a series of tweets questioning the prices of their insulin drugs. Moreover, Sen. Sanders and Rep. Cummings have asked the Justice Department and the Federal Trade Commission (FTC) to investigate potential collusion among pharmaceutical companies that manufacture diabetes products.
According to the lawmakers, insulin medication prices have tripled between 2002 and 2013, from $231 to $736 per year per patient. As per information provided in the letter to the DoJ and the FTC, the price of Sanofi’s Lantus shot up 168% from 2010 to 2014 while that of Lilly’s Humalog shot up 103% and that of Merck’s (MRK - Free Report) Januvia and Janumet by 75% each. Merck is a Zacks Rank #2 (Buy) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Novartis Breast Cancer Treatment Gets Priority Review: Novartis’ (NVS - Free Report) experimental breast cancer treatment, LEE011 (ribociclib) was granted Priority Review by the FDA for the first-line treatment of postmenopausal women with HR+/HER2- advanced or metastatic breast cancer in combination with Femara (letrozole). LEE011 plus Femara was shown to reduce the risk of progression or death by 44% compared to Femara alone. The candidate is also being reviewed by the European Medicines Agency (EMA).
Astellas to Acquire Ganymed, Strengthen Cancer Pipeline: Astellas Pharma announced that it will be acquiring Germany based Ganymed Pharmaceuticals AG, a biopharmaceutical company focused on the development of a new class of immunotherapeutic cancer drugs called ideal monoclonal antibodies (IMABs).
The acquisition could see Astellas shelling out up to €1.282 billion including €422 million for 100% of the equity in Ganymed. The balance would be payable on the achievement of milestones related to the development of IMAB362, which is being evaluated for cancer, a key focus areas as well as growth driver for Astellas. IMAB362 has orphan drug status in the U.S. and Europe for gastric and pancreatic cancer.
Performance
Large Cap Pharmaceuticals Industry Price Index
Large Cap Pharmaceuticals Industry Price Index
Pfizer’s shares declined 6.0% reflecting the disappointing earnings report. The NYSE ARCA Pharmaceutical Index declined 2.3% over the last five trading days. Over the last six months, Bristol-Myers (BMY - Free Report) declined 27.9% while Merck was up 7.3% (See the last pharma stock roundup here: Bristol-Myers, Merck Top Estimates, Merck Wins Key FDA Nod).
What's Next in the Pharma World?
Companies like Mylan, Endo and AstraZeneca (AZN - Free Report) will be reporting earnings results in the coming days. Moreover, a decision from the FDA regarding Bristol-Myers’ Opdivo for head and neck cancer should be out by Nov 11.
Now See Our Private Investment Ideas
While the above ideas are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>